 |
 |
 |
|
 |
articles < press << main |
 |
 |
|
|
|
|
|
|
|
| date | | | | title / topic / summary | sort by topic |
|---|
|
| 06/14/2006 | | | | Nymox Signs New Sales and Marketing Agreement for Alzheimer's Test with Kyung Min Meditech Co. Ltd. In Korea
topic: no topic
June 14, 2006: Nymox announced today that it has entered into an agreement with Kyung Min Meditech Co., Ltd.
for the marketing and sale of the Company's AlzheimAlert™ kit in the Korea Republic. |
| 06/09/2006 | | | | Nymox Reports Completion of NX-1207 Dosing in Current Multi-Center BPH Drug Trial
topic: no topic
June 9, 2006: Nymox announced today that patient dosing in the Company's multi-center Phase 2 clinical trial
of NX-1207 is completed this week. NX-1207 is Nymox's lead drug candidate for the treatment of benign prostatic hyperplasia (BPH), a common affliction of men over the age of 50. |
| 06/08/2006 | | | | Nymox Pharmaceutical Corporation Holds Annual Shareholders Meeting
topic: Appointments
June 8, 2006: The annual general meeting of the shareholders of Nymox
Pharmaceutical Corporation was highlighted by an update and review of
current product development by the Company's President and CEO, Dr. Paul Averback. Newly
elected to the Board of Directors were Professor David Morse, Ph.D., Roger Guy, M.D., Paul F. McDonald, and Randall Lanham. |
| 05/19/2006 | | | | New Study Links Second-Hand Smoke to Allergy Risk for Infants
topic: Tobacco Exposure Tests
May 19, 2006: Heavy exposure to second-hand smoke at home nearly tripled the risk that an infant will develop allergic rhinitis by age 1, according to a new study. Nymox's TobacAlert™ product allows for an easy-to-use, cost-effective means of on-site
testing for second-hand smoke exposure. |
| 05/18/2006 | | | | Updated Analyst Reports Give Nymox “Buy” Recommendation
topic: Financial
May 18, 2006: Three current independent analyst reports have
“buy” recommendations for Nymox Pharmaceutical Corporation. |
| 05/17/2006 | | | | Nymox AlzheimAlert™ Findings To Be Presented at the XXVIIIth International Congress of Clinical Neurophysiology
topic: AlzheimAlert™ & Diagnosis of Alzheimer's Disease
May 17, 2006: Nymox is pleased to announce that positive results from successful clinical studies of the
Company's AlzheimAlert™ test will be presented at the upcoming International Congress
of Clinical Neurophysiology to be held in Edinburgh, UK from September 10 to 14, 2006. |
| 05/16/2006 | | | | Nymox Reports Positive New Efficacy Data for Benign Prostatic Hyperplasia Drug
topic: R&D: BPH (enlarged prostate) Treatments
May 16, 2006: Nymox is
pleased to release today long term efficacy results from the open-label Phase 1-2 testing
of NX-1207, the Company's investigational new drug for benign prostatic hyperplasia (BPH).
The new data indicates that at 29-34 months after initial treatment, there was highly
significant symptomatic improvement. Comparison to a control group showed that NX-1207
efficacy results reached statistical significance. There were no serious safety issues
reported in individuals treated with NX-1207. |
| 05/15/2006 | | | | Nymox Reports First Quarter 2006 Financial Results
topic: Financial
May 15, 2006: Nymox announced today its financial results for the first quarter of 2006. |
| 05/12/2006 | | | | New Study of Infants Highlights Second Hand Smoke Risk
topic: Tobacco Exposure Tests
May 12, 2006: A new study of the infants of mothers who smoke
found significant levels of nicotine, cotinine and carcinogens in the babies' urine,
highlighting the risk second-hand smoke exposure poses for young children. |
| 05/10/2006 | | | | Nymox AlzheimAlert™ Findings To Be Presented at the 4th Bologna International Meeting on Affective, Behavioral and Cognitive Disorders in the Elderly
topic: AlzheimAlert™ & Diagnosis of Alzheimer's Disease
May 10, 2006: Nymox is
pleased to announce that positive results from successful clinical studies of the Company's AlzheimAlert™ test will be presented at the 4th Bologna International Meeting on Affective, Behavioral and Cognitive Disorders in the Elderly to be held in Bologna, Italy from June 15 to 17, 2006. |
|